The interference of FGF-2 with HPSE [29] as well as TGF-β [30] and IGF-2 [31] for CD222 activity in the tumor microenvironments may modulate epithelial-mesenchymal interactions [20]. The gene discussed is IGF2R; the disease is neoplasm.